Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b for Antiangiogenic/Antivascular Effect in Adult Advanced Neoplasm (METRO1)

NCT00908869 Phase 1 COMPLETED

Purpose: This phase I trial estimates the antiangiogenic and antivascular effect of 4 different levels of continuous low doses of the combination of Vinorelbine, Cyclophosphamide and Interferon alpha 2b (" metronomic chemotherapy ")in adult advanced neoplasm. This study is non randomized, monocentric, and with a pharmacodynamic part. Primary objective: Estimation of the toxicity of the combination of continuous low doses of Vinorelbine, Cyclophosphamide and Interferon alpha 2b. Secondary objectives: Estimation of the antiangiogenic and/or antivascular effect (VEGF measurement) in radiography (DEC-MRI), biology and immunohistochemistry of the treatment.

Details

Lead sponsor	Institut Paoli-Calmettes
Phase	Phase 1
Status	COMPLETED
Enrolment	30
Start date	2006-05
Completion	2011-05

Conditions

• Advanced Neoplasm

Interventions

• Vinorelbine, Cyclophosphamide and Interferon alpha 2b

Primary outcomes

• Estimation of the toxicity of the combination of continuous low doses of Vinorelbine, Cyclophosphamide and Interferon alpha 2b. — 6 weeks

Countries

France